Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A case report of ruxolitinib reversing myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYunfang YangTNTing NiuLPLing Pan

Discussion

Loading...

Member takes

Overview

Case report reveals ruxolitinib treatment significantly improved symptoms and reduced spleen size in a patient with primary myelofibrosis.

Key Points

  • Ruxolitinib treatment reduced symptoms of fatigue and abdominal pain, leading to improved quality of life.
  • The MPN-10 score decreased from 46 to 36 points within three months of ruxolitinib treatment.
  • Observational analysis of treatment outcomes showed myelofibrosis degree improved from MF-3 to MF-1 after 15 months.
  • Long-term treatment with ruxolitinib successfully maintained patient health and spleen size stability at 5 cm below the costal margin.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2c3https://doi.org/10.1182/blood-2025-6480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Significant improvement of bone marrow fibrosis in patients with chronic myeloproliferative neoplasms (CMPN) treated with ruxolitinib.2025
  2. 2Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center2025
  3. 3Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study2025 · 5 citations
  4. 4Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations
  5. 5Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis2025 · 1 citations